{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:50:27Z","timestamp":1788393027867,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ad.2013.01.009","type":"journal-article","created":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T11:30:55Z","timestamp":1367321455000},"page":"655-662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efectos adversos cut\u00e1neos del imatinib (inhibidor de la tiros\u00edn cinasa)"],"prefix":"10.1016","volume":"105","author":[{"given":"M.","family":"Pretel-Irazabal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tuneu-Valls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ormaechea-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2013.01.009_bib0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.seminoncol.2004.03.038","article-title":"Molecularly targeted treatment for dermatofibrosarcoma protuberans","volume":"3","author":"McArthur","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ad.2013.01.009_bib0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ad.2013.01.009_bib0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.semarthrit.2012.06.001","article-title":"Therapeutic inhibition of tyrosine kinases in systemic sclerosis: A review of published experience on the first 108 patients treated with imatinib","volume":"42","author":"Bournia","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.01.009_bib0020","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.ad.2013.01.009_bib0025","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ad.2011.10.019","article-title":"KIT mutations in a series of melanomas and their impact on treatment with imatinib","volume":"103","author":"Botella-Estrada","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2013.01.009_bib0030","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ad.2013.01.009_bib0035","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Cancer Therapy Evaluation Program [Internet]. Bethesda: National Cancer Institute [citado 31 Oct 2012]. Disponible en: http:\/\/evs-nci.nih.gov\/ftpl\/CTCAE\/About.html"},{"key":"10.1016\/j.ad.2013.01.009_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-011-0729-7","article-title":"The safety profile of imatinib in CML and GIST: Long-term considerations","volume":"86","author":"Thanopoulou","year":"2012","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.ad.2013.01.009_bib0045","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2013.01.009_bib0050","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2013.01.009_bib0055","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2013.01.009_bib0060","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ad.2013.01.009_bib0065","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2013.01.009_bib0070","first-page":"465","article-title":"Skin and oral lesions associated to imatinib mesylate therapy","volume":"17","author":"Basso","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ad.2013.01.009_bib0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI-571) in Philadelphia chromosome positive leukemias: a prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.beha.2009.06.001","article-title":"Management of drug toxicities in chronic myeloid leukaemia","volume":"22","author":"Mauro","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.ad.2013.01.009_bib0085","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2013.01.009_bib0090","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJM200108233450814","article-title":"Cutaneous reactions to STI571","volume":"345","author":"Brouard","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2013.01.009_bib0095","first-page":"979","article-title":"The use of imatinib (STI571) in chronic myeloid leukemia: Some practical considerations","volume":"87","author":"Marin","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.ad.2013.01.009_bib0100","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0125","article-title":"NCCN Task Force Report. Tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia","volume":"9","author":"O\u2019Brien","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ad.2013.01.009_bib0105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1081-1206(10)60016-6","article-title":"Desensitization to imatinib in patients with leukemia","volume":"97","author":"Nelson","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.ad.2013.01.009_bib0110","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","article-title":"Indications for imatinib mesylate therapy and clinical management","volume":"9","author":"Guilhot","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.ad.2013.01.009_bib0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/shem.2003.50038","article-title":"Imatinib treatment specific issues: related to safety, fertility and pregnancy","volume":"40","author":"Hensley","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ad.2013.01.009_bib0120","first-page":"228","article-title":"Imatinib mesylate and dermatology, part 2: A review of the cutaneous side effects of imatinib mesylate","volume":"5","author":"Scheinfeld","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.suponc.2011.08.001","article-title":"Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: The role of the midlevel practitioner","volume":"10","author":"Cornelison","year":"2012","journal-title":"J Support Oncol"},{"key":"10.1016\/j.ad.2013.01.009_bib0130","first-page":"73","article-title":"Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature","volume":"90","author":"Kuraishi","year":"2010","journal-title":"Acta DermVenereol"},{"key":"10.1016\/j.ad.2013.01.009_bib0135","first-page":"325","article-title":"Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia","volume":"89","author":"Kawakami","year":"2009","journal-title":"Acta DermVenereol"},{"key":"10.1016\/j.ad.2013.01.009_bib0140","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/09546630410015556","article-title":"Oral lichenoid eruption secondary to imatinib (Glivec)","volume":"15","author":"Ena","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2013.01.009_bib0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4103\/0378-6323.16627","article-title":"Lichenoid eruption due to imatinib","volume":"71","author":"Prabhash","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ad.2013.01.009_bib0150","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/j.1365-2133.2006.07276.x","article-title":"Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect","volume":"154","author":"Dalmau","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0155","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00043426-200403000-00016","article-title":"Hypopigmentation from imatinib mesylate (Gleevec)","volume":"26","author":"Grossman","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ad.2013.01.009_bib0160","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdh068","article-title":"Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"15","author":"Arora","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ad.2013.01.009_bib0165","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJM200208083470614","article-title":"Imatinib mesylate and gray hair","volume":"347","author":"Etienne","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2013.01.009_bib0170","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/j.jcms.2011.07.010","article-title":"Imatinib-associated hyperpigmentation of the palate in post-HSCT patient","volume":"40","author":"Resende","year":"2012","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ad.2013.01.009_bib0175","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.tripleo.2010.11.006","article-title":"Oral pigmentation in the hard palate associated with imatinib mesylate therapy: A report of three cases","volume":"111","author":"Mattsson","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.ad.2013.01.009_bib0180","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-3083.2008.02706.x","article-title":"Imatinib-associated hyperpigmentation, a side effect that should be recognized","volume":"23","author":"McPherson","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2013.01.009_bib0185","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1034\/j.1600-0749.2003.00055.x","article-title":"The role of Kit-ligand in melanocyte development and epidermal homeostasis","volume":"16","author":"Wehrle-Haller","year":"2003","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.ad.2013.01.009_bib0190","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/moe.2000.106340","article-title":"Oral mucosal hyperpigmentation secondary to antimalarial drug therapy","volume":"90","author":"Kleinegger","year":"2000","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.ad.2013.01.009_bib0195","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1346-8138.2007.00369.x","article-title":"Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib","volume":"34","author":"Woo","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0200","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1440-0960.2008.00495.x","article-title":"Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour","volume":"50","author":"Cheng","year":"2009","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0205","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1365-2133.2006.07262.x","article-title":"Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia","volume":"154","author":"Deguchi","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0210","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1046\/j.1365-2133.2002.497217.x","article-title":"Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour","volume":"147","author":"Miyagawa","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0215","doi-asserted-by":"crossref","first-page":"e1022","DOI":"10.1111\/j.1365-2230.2009.03696.x","article-title":"T-regulatory cell response in psoriasis and changes with imatinib therapy","volume":"34","author":"Thachil","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0220","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000063900","article-title":"Pityriasis rosea associated with imatinib (STI571, Gleevec)","volume":"205","author":"Konstantopoulos","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2013.01.009_bib0225","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jaad.2004.10.888","article-title":"Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases","volume":"5","author":"Brazzelli","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0230","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5021\/ad.2011.23.S3.S360","article-title":"Pityriasis rosea-like drug eruption induced by imatinib mesylate (Gleevec\u2122)","volume":"23","author":"Cho","year":"2011","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0235","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.leukres.2004.05.015","article-title":"Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy","volume":"29","author":"Dib","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.ad.2013.01.009_bib0240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000051705","article-title":"Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia","volume":"203","author":"Brouard","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2013.01.009_bib0245","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1034\/j.1600-0609.2002.02830.x","article-title":"Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia","volume":"69","author":"Schwarz","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ad.2013.01.009_bib0250","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000088510","article-title":"Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia","volume":"211","author":"Gambillara","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2013.01.009_bib0255","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1365-2141.2002.37133.x","article-title":"Sti571-induced Stevens-Johnson syndrome","volume":"119","author":"Vidal","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ad.2013.01.009_bib0260","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/0378-6323.16628","article-title":"Imatinib induced Stevens-Johnson syndrome: Lack of recurrence following re-challenge with a lower dose","volume":"71","author":"Pavithran","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.ad.2013.01.009_bib0265","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000218097","article-title":"Stevens-Johnson syndrome induced by combination of imatinib and allopurinol","volume":"55","author":"Hsieh","year":"2009","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ad.2013.01.009_bib0270","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1365-2141.2002.03499.x","article-title":"Stevens-Johnson syndrome after treatment with STI571: A case report","volume":"117","author":"Hsiao","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ad.2013.01.009_bib0275","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00277-007-0265-y","article-title":"Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose","volume":"86","author":"Mahapatra","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ad.2013.01.009_bib0280","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/archderm.141.3.368","article-title":"Imatinib-induced Sweet syndrome in a patient with chronic myeloid leukemia","volume":"141","author":"Ayirookuzhi","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0285","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0145-2126(03)00257-1","article-title":"Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking imatinib mesylate","volume":"28","author":"Liu","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.ad.2013.01.009_bib0290","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.2003.04151_4.x","article-title":"A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI571, Glivec)","volume":"120","author":"Drummond","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ad.2013.01.009_bib0295","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.annder.2010.11.009","article-title":"Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib","volume":"138","author":"De Masson","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.ad.2013.01.009_bib0300","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1056\/NEJMc053425","article-title":"Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia","volume":"354","author":"Assouline","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2013.01.009_bib0305","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1365-2133.2003.05594.x","article-title":"Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib","volume":"149","author":"Ugurel","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0310","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1365-4632.2010.04774.x","article-title":"Imatinib mesylate-induced neutrophilic folliculitis in a teenager","volume":"51","author":"Garc\u00eda-Romero","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0315","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00277-003-0643-z","article-title":"Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Schaich","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ad.2013.01.009_bib0320","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1046\/j.1365-2141.2003.04208_3.x","article-title":"Photosensitization in chronic myelogenous leukemia patients treated with imatinib mesylate","volume":"120","author":"Rousselot","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ad.2013.01.009_bib0325","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0781.2011.00621.x","article-title":"Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate","volume":"28","author":"Brazzelli","year":"2012","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.ad.2013.01.009_bib0330","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.0303-6987.2003.053.x","article-title":"Mycosis fungoides-like reaction in a patient treated with Gleevec","volume":"30","author":"Clark","year":"2003","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ad.2013.01.009_bib0335","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2003.04277.x","article-title":"Precipitation of porphyria cutanea tarda by imatinib mesylate?","volume":"121","author":"Ho","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ad.2013.01.009_bib0340","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1365-2230.2008.02985.x","article-title":"Imatinib-induced pseudoporphyria","volume":"34","author":"Timmer-de Mik","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0345","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2230.2011.04289.x","article-title":"Skin fragility and blistering secondary to imatinib","volume":"37","author":"Reddy","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2013.01.009_bib0350","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1468-3083.2009.03456.x","article-title":"Skin fragility and blistering with imatinib mesylate","volume":"24","author":"Verma","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731013001087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731013001087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:01:47Z","timestamp":1757552507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731013001087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0001731013001087"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2013.01.009","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectos adversos cut\u00e1neos del imatinib (inhibidor de la tiros\u00edn cinasa)","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2013.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Espa\u00f1a, S.L.U. y AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}